Who is sponsoring NCT00227773?

NCT00227773 is sponsored by Eastern Cooperative Oncology Group.

What drugs are being tested in NCT00227773?

Interventions in NCT00227773: octreotide acetate, vatalanib, anti-cytokine therapy, antiangiogenesis therapy, biological therapy, endocrine therapy, enzyme inhibitor therapy, growth factor antagonist therapy, hormone therapy, protein tyrosine kinase inhibitor therapy, somatostatin analogue therapy.

What condition does NCT00227773 study?

NCT00227773 studies Gastrointestinal Carcinoid Tumor, Islet Cell Carcinoma.

Is NCT00227773 still recruiting?

NCT00227773 is currently withdrawn. Last updated 8 October 2015.

Last reviewed 2015-10-08 · How we verify

NCT00227773

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Vatalanib and Octreotide in Treating Patients With Progressive Neuroendocrine Tumors

Withdrawn Phase 2 Last updated 8 October 2015

What this trial tests

Phase 2 trial testing octreotide acetate in Gastrointestinal Carcinoid Tumor. Withdrawn.

Quick facts

Lead sponsor	Eastern Cooperative Oncology Group
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Primary purpose	treatment

Drugs / interventions tested

octreotide acetate — full drug profile →
vatalanib — full drug profile →
anti-cytokine therapy
antiangiogenesis therapy
biological therapy
endocrine therapy (endocrine-therapy) — full drug profile →
enzyme inhibitor therapy — full drug profile →
growth factor antagonist therapy — full drug profile →
hormone therapy
protein tyrosine kinase inhibitor therapy
somatostatin analogue therapy

Conditions studied

Gastrointestinal Carcinoid Tumor — all drugs for Gastrointestinal Carcinoid Tumor →
Islet Cell Carcinoma — all drugs for Islet Cell Carcinoma →

Sponsor

Eastern Cooperative Oncology Group

Who can join

Adults 18 to 120, any sex, with Gastrointestinal Carcinoid Tumor or Islet Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by stopping blood flow to the tumor. Octreotide may help control symptoms, such as diarrhea, caused by the tumor. Giving vatalanib together with octreotide may be an effective treatment for neuroendocrine tumors. PURPOSE: This phase II trial is studying how well giving vatalanib together with octreotide works in treating patients with progressive neuroendocrine tumors.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Treatment of gastrointestinal neuroendocrine tumors with inhibitors of growth factor receptors and their signaling pathways: recent advances and future perspectives.
Höpfner M, Schuppan D, Scherübl H. · · 2008 · cited 13× · PMID 18442192 · DOI 10.3748/wjg.14.2461

Verify or expand the search:

Other trials of octreotide acetate

Trials testing the same drug.

NCT00002864 — Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer · Phase 3 · completed

Other Eastern Cooperative Oncology Group trials

Trials by the same sponsor.

NCT07068074 — A Randomized Phase III Study of Management of Treatment Naive Primary Melanoma in Elderly Patients · Phase 3 · not yet recruiting
NCT07040280 — Testing the Effect of Sulforaphane, a Compound Naturally Found in Cruciferous Vegetables, on Preventing Melanoma in Pati · Phase 2 · not yet recruiting
NCT07122492 — A Targeted Electronic Health Approach to Reduce Fear of Recurrence in Breast Cancer Survivors (FoRtitude) · NA · not yet recruiting
NCT07085728 — Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatm · Phase 2 · not yet recruiting
NCT06756607 — The ECOG-ACRIN SUPPORT Trial: Multilevel Intervention to Improve Diverse Enrollment in Cancer Clinical Trials · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00227773 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Eastern Cooperative Oncology Group
Last refreshed: 8 October 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00227773.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing